Outline
Early Public Offering | Monogram

Monogram is a medical device company that develops joint reconstruction products. It has focused its efforts thus far on knee replacements, but sees possible applications for its technology in hip replacements as well in the future. The company is raising a maximum $30M Series B Preferred round at a $75 million pre-money valuation ($6.27 per share, excluding the effect of bonus shares). Investors who take advantage of all available bonus shares will invest at an effective $5.70 per share. Monogram intends to use these funds primarily to advance product development, fund its 501(k) pre-market submission of the total knee and robotic system, and fund employee costs. While Monogram expects to generate revenue in 2021 by acting as a wholesale distributor of generic implants from other manufacturers, its success as an investment will come from its ability to develop and commercialize its proprietary implant and robot.

The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
Reg A+
Robotics
MedTech
New Campaign
  • Raised
    $5mm+
  • Investors on Seedinvest
    3,600
Learn More & Invest

Analysis Summary

Health Score
86
%
Market Size
99
%
Traction
80
%
Team
95
%
Competition
75
%

EPO Independent Analysis

Monogram is a medical device company that develops joint reconstruction products. It has focused its efforts thus far on knee replacements, but sees possible applications for its technology in hip replacements as well in the future. The company is raising a maximum $30M Series B Preferred round at a $75 million pre-money valuation ($6.27 per share, excluding the effect of bonus shares). Investors who take advantage of all available bonus shares will invest at an effective $5.70 per share. Monogram intends to use these funds primarily to advance product development, fund its 501(k) pre-market submission of the total knee and robotic system, and fund employee costs. While Monogram expects to generate revenue in 2021 by acting as a wholesale distributor of generic implants from other manufacturers, its success as an investment will come from its ability to develop and commercialize its proprietary implant and robot.

Want the full EPO analysis?

The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.
The Investor Brief will be delivered to your inbox shortly
Oops! Something went wrong while submitting the form.

Monogram is a medical technology company ushering in the future of joint reconstruction by developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics.

  • World-class team with a track record of execution
  • Expect revenues in 2021
  • Already raised $16.7M from 6,793 investors
  • Established product-market fit
  • Novel technology for massive growing market
  • The joint replacement market is approximately $19.6BN, with over 1 million knee replacements per year

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view Monogram Orthopedics offering circular as well as the risks associated with this offering.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here.